pharmaceuticalcommerce10 小时
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...